A Phase 2 interventional study of TATE and pembrolizumab and TAS-102 pill in Colorectal Cancer; Lung Cancer, sponsored by Teclison Ltd.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Teclison Ltd. · Phase 2, Interventional, and Treatment
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
This study is an open-label study to treat patients with refractory metastatic colorectal cancer and non-small cell lung cancer with liver metastasis. Patients enrolled in the mCRC cohort will be randomized to receive study treatment Trans-arterial Tirapazamine Embolization (TATE)+Pembrolizumab or FDA-approved standard of care, such as TAS-102 or regorafenib, and their Overall Survival (OS) will be compared in the two cohorts as the primary endpoint. Patients enrolled in the NSCLC cohort will all receive study treatment TATE+Pembrolizaumb and Overall Response Rate (ORR) will be the primary endpoint.
Exclusion Criteria:
metastatic colorectal cancer progressed on at least two lines of chemotherapy
Drug: TATE and pembrolizumab · Drug: TAS-102 pill · Drug: Regorafenib Pill
Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
Drug: TATE and pembrolizumab
All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.
Also known as: TATE: Trans-arterial Tirapazamine Embolization;
The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.
Also known as: LONSURF
As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.
Also known as: STIVARGA
Overall Survival for the mCRC cohort
From the first day of treatment to death
Time frame: 24 months
Overall Response Rate (ORR) for the NSCLC cohort
Per RECIST 1.1 criteria
Time frame: within 24 months
Duration of Response
per RECIST 1.1
Time frame: 24 months
Response rate
in TATE treated or TATE-untreated lesions by RECIST and mRECIST
Time frame: 24 months
PFS
Progression Free Survival
Time frame: 24 months
TTP
Time to Progression
Time frame: 24 months
Plan to share: No — International meeting report or medical Journal publication
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teclison Ltd.